Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 5Neoplasms 3Recurrence 1Neuroectodermal Tumors 1Medulloblastoma 1Brain Neoplasms 1

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Lomustine × Clear all
NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡